泰恩康(301263.SZ)是一家專注於研發、生產、銷售及代理運營醫藥產品、醫療器械
格隆匯8月9日丨泰恩康(301263.SZ)在投資者互動平台表示,公司是一家專注於研發、生產、銷售及代理運營醫藥產品、醫療器械、並提供醫藥技術服務與轉讓的綜合性醫藥創新企業,核心產品有和胃整腸丸、“愛廷玖”鹽酸達泊西汀片、“愛廷威”他達拉非片、“沃麗汀”卵磷脂絡合碘片等。研發創新方面,子公司山東華鉑凱盛生物科技有限公司和江蘇博創園生物醫藥科技有限公司作為泰恩康的兩大研發中心;生產佈局方面,隨着安徽泰恩康化藥、生物藥生產基地及四川泰恩康原料藥生產基地的建設完成,廣東泰恩康生物科技的生產轉型升級,公司已擁有原料藥、化學藥、生物藥、中成藥、外用藥、醫療器械等多個生產基地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.